JP2023553534A - 癌の処置のための併用療法 - Google Patents

癌の処置のための併用療法 Download PDF

Info

Publication number
JP2023553534A
JP2023553534A JP2023560241A JP2023560241A JP2023553534A JP 2023553534 A JP2023553534 A JP 2023553534A JP 2023560241 A JP2023560241 A JP 2023560241A JP 2023560241 A JP2023560241 A JP 2023560241A JP 2023553534 A JP2023553534 A JP 2023553534A
Authority
JP
Japan
Prior art keywords
compound
formula
cancer
kras
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560241A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022125971A5 (https=
JP2023553534A5 (https=
Inventor
マーティン，リーナス
ハリス ブライル，レスリー
フィールド シューメーカー，ロバート
Original Assignee
エラスカ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラスカ，インク． filed Critical エラスカ，インク．
Publication of JP2023553534A publication Critical patent/JP2023553534A/ja
Publication of JPWO2022125971A5 publication Critical patent/JPWO2022125971A5/ja
Publication of JP2023553534A5 publication Critical patent/JP2023553534A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023560241A 2020-12-11 2021-12-10 癌の処置のための併用療法 Pending JP2023553534A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063124669P 2020-12-11 2020-12-11
US63/124,669 2020-12-11
US202163214736P 2021-06-24 2021-06-24
US63/214,736 2021-06-24
US202163277555P 2021-11-09 2021-11-09
US63/277,555 2021-11-09
US202163283035P 2021-11-24 2021-11-24
US63/283,035 2021-11-24
PCT/US2021/062927 WO2022125971A1 (en) 2020-12-11 2021-12-10 Combination therapies for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2023553534A true JP2023553534A (ja) 2023-12-21
JPWO2022125971A5 JPWO2022125971A5 (https=) 2024-12-17
JP2023553534A5 JP2023553534A5 (https=) 2024-12-17

Family

ID=81974015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560241A Pending JP2023553534A (ja) 2020-12-11 2021-12-10 癌の処置のための併用療法

Country Status (7)

Country Link
US (1) US20250195533A1 (https=)
EP (1) EP4259639A4 (https=)
JP (1) JP2023553534A (https=)
KR (1) KR20230151981A (https=)
AU (1) AU2021397319A1 (https=)
CA (1) CA3201612A1 (https=)
WO (1) WO2022125971A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
WO2023059771A1 (en) * 2021-10-06 2023-04-13 Erasca, Inc. Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
PL4426303T3 (pl) * 2021-11-02 2026-02-09 Semmelweis Egyetem Inhibitory transferazy farnezylowej i inhibitory kras do leczenia nowotworów z mutacją kras
PE20251110A1 (es) * 2022-08-19 2025-04-22 Mirati Therapeutics Inc Composiciones farmaceuticas solidas de adagrasib

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061103A1 (en) * 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
WO2020118066A1 (en) * 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
JP2020105162A (ja) * 2018-11-19 2020-07-09 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020165732A1 (en) * 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670231B2 (en) * 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
EA201992781A1 (ru) * 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
JP2023553533A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
JP2023553532A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061103A1 (en) * 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
JP2020105162A (ja) * 2018-11-19 2020-07-09 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020118066A1 (en) * 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
WO2020165732A1 (en) * 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER DISCOVERY, vol. 10, no. 1, JPN6025046956, January 2020 (2020-01-01), pages 54 - 71, ISSN: 0005731658 *
CLINICAL CANCER RESEARCH, vol. 26, no. 7, JPN6025046957, 1 April 2020 (2020-04-01), pages 1633 - 1643, ISSN: 0005731659 *

Also Published As

Publication number Publication date
WO2022125971A1 (en) 2022-06-16
EP4259639A1 (en) 2023-10-18
EP4259639A4 (en) 2024-10-23
AU2021397319A1 (en) 2023-07-27
AU2021397319A9 (en) 2024-05-16
CA3201612A1 (en) 2022-06-16
KR20230151981A (ko) 2023-11-02
US20250195533A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
US20240293422A1 (en) Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
JP2023553534A (ja) 癌の処置のための併用療法
JP6388859B2 (ja) 抗ｈｅｒ２抗体−薬剤コンジュゲートと化学療法剤の併用及び使用方法
JP2022115924A (ja) グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
KR20230154793A (ko) 암 치료를 위한 병용 요법
JP2023553533A (ja) 癌の処置のための併用療法
TW202600167A (zh) 用抗pd-l1抗體治療癌症之方法
TW202011991A (zh) 用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
CN117120449A (zh) 用于癌症治疗的联合疗法
HK40103172A (zh) 用於癌症治疗的联合疗法
US20240285624A1 (en) Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
CN117083283A (zh) 用于癌症治疗的联合疗法
HK40103380A (zh) 用於癌症治疗的联合疗法
HK40103377A (zh) 用於癌症治疗的联合疗法
CN117098537A (zh) 用于癌症治疗的联合疗法
WO2025226830A1 (en) Shp2 and egfr inhibitors for the treatment of chordoma
WO2023059771A1 (en) Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
TW202348626A (zh) 用莫蘇妥珠單抗及來那度胺治療復發性／難治性濾泡性淋巴瘤之方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251119